RARE DISEASERESEARCH ATLAS
Open navigation menu

ORPHA:79284

Methylmalonic acidemia with homocystinuria type cblF

medium confidenceSubtype of disorder

Also known as: CblF defect · Cobalamin F defect · Combined defect in adenosylcobalamin and methylcobalamin synthesis, type cblF · Lysosomal membrane cobalamin transporter deficiency · Methylmalonic aciduria with homocystinuria, type cblF

Query health: suspect — Only one of 2 strategies returned hits (phrase).

Publications

398

75.4th percentile

Trials

0

Interventional, condition-specific

Researchers

108

Distinct authors in sample

Gene link

LMBRD1

Definitive

Readiness

4/6

Stages with a signal

Clinical definition (Orphanet)

cblF type methylmalonic acidemia with homocystinuria is a form of methylmalonic acidemia with homocystinuria, an inborn error of vitamin B12 (cobalamin) metabolism characterized by megaloblastic anemia, lethargy, , , intellectual deficit and .

How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.

Orphanet entry

Cross-references

Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.

Additional Mondo synonyms (7)

cblF defect · cobalamin F defect · combined defect in adenosylcobalamin and methylcobalamin synthesis, type cblF · inherited methylmalonic acidemia and homocystinuria · lysosomal membrane cobalamin transporter deficiency · methylmalonic aciduria and homocystinuria type cblF · methylmalonic aciduria with homocystinuria, type cblF

Research stages

Trial readiness signals

Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”

4/6 stages with a signal

No specific-condition interventional trial, but broader-category trials exist — discuss eligibility with a clinician.

  1. Gene identifiedPresent

    Definitive — LMBRD1

  2. LiteraturePresent

    398 matched papers (297 in last 10 years) Source

  3. Phenotype characterisedPresent

    67 HPO annotations (e.g. Megaloblastic anemia; Hyperhomocystinemia; Decreased circulating adenosylcobalamin concentration) Source

  4. Animal modelNot found

    No Alliance genotype “model of” associations via Monarch for these Mondo IDs

  5. Orphan designationNot found

    No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source

  6. Interventional trialPartial

    None under the specific name; 15 for broader category methylmalonic acidemia

Biology

Genes and phenotypes

Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.

Do we know what causes it?

Yes — we know a specific gene responsible (LMBRD1).

GenCC classification: Definitive.

Phenotypes (Monarch / HPO)

67

Associated phenotypes · MONDO:0010183

  • Megaloblastic anemia
  • Hyperhomocystinemia
  • Decreased circulating adenosylcobalamin concentration
  • Hypotonia
  • Failure to thrive

Showing 5 of 67 — open Monarch for the full list.

Animal models (Monarch / Alliance)

None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.

Monarch fetch 2026-07-29

Therapies

Designations, candidates, and chemicals

FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.

Orphan designation (FDA · EMA)

No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.

Open Targets candidates

No drugs or clinical candidates returned for this Mondo ID on Open Targets.

CTD chemicals (MyDisease.info)

No CTD chemical associations returned for this Mondo ID.

Literature

Is anyone studying this?

398

398 papers have ever been published on this condition (under this name). For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.

398 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).

297 in the last 10 years · medium confidence · 75.4th percentile (publications denominator)

Phrase hits: 18 · MeSH hits: 0

Open Europe PMC search

Who's working on it?

108

Distinct author names in 18 sampled papers — named people below.

Who's working on it?

No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.

  1. 01
    Fowler B6 papers · 2017

    Basel, Switzerland

    Papers in Europe PMC
  2. 02
    Rutsch F5 papers · 2016

    Department of General Pediatrics, Münster University Children's Hospital, Albert-Schweitzer-Strasse 33, D-48149 Münster, Germany. rutschf@mednet.uni-muenster.de

    Papers in Europe PMC
  3. 03
    Suormala T5 papers · 2017

    Division of Metabolism and Children's Research Center, University Children's Hospital, CH-8032 Zurich, Switzerland.

    Papers in Europe PMC
  4. 04
    Rosenblatt DS4 papers · 2012
    Papers in Europe PMC
  5. 05
    Baumgartner MR3 papers · 2017

    Division of Metabolism and Children's Research Center, University Children's Hospital, CH-8032 Zurich, Switzerland; Rare Disease Initiative Zurich (radiz), Clinical Research Priority Program for Rare Diseases, University of Zurich, CH-8006 Zurich, Switzerland; Zurich Center for Integrative Human Physiology, University of Zurich, CH-8006 Zurich, Switzerland. Electronic address: matthias.baumgartner@kispi.uzh.ch.

    Papers in Europe PMC
  6. 06
    Buers I3 papers · 2016

    Department of General Pediatrics, Müenster University Children's Hospital, Müenster, Germany.

    Papers in Europe PMC
  7. 07
    Gailus S3 papers · 2011

    Department of General Pediatrics, Münster University Children's Hospital, Germany.

    Papers in Europe PMC
  8. 08
    Miousse IR3 papers · 2012
    Papers in Europe PMC
  9. 09
    Nürnberg P3 papers · 2012
    Papers in Europe PMC
  10. 10
    Stucki M3 papers · 2012
    Papers in Europe PMC

Clinical research

Is a treatment being tested?

0

interventional trials for this specific condition

No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present). 15 trials are registered for methylmalonic acidemia, the broader category — shown separately because they may or may not enrol this specific subtype.

Data as of 11 September 2026 · last trial check 11 September 2026

No matched interventional trials. This is true for 77.2% of diseases in the trials denominator (5501 of 7126). Here are the researchers publishing on it.

medium confidence · 38.6th percentile (trials denominator)

Recruiting interventional trials

From the matched ClinicalTrials.gov set

No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.

15 interventional trials matched methylmalonic acidemia, the broader category — listed below. Those studies are not counted in the condition-specific total.

Broader category: methylmalonic acidemia

15

Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.

Worth raising with a clinician. How we count trials.

Recruiting under the broader category

Other registries (secondary)

Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.

raw 0 · after dedupe 0 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 0 · dropped 0 · fetched 2026-07-30

Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri

No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).

Where to find support

Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.

Orphanet entry for Methylmalonic acidemia with homocystinuria type cblF — check Associations / patient organisations on that page.

India — NPRD

Last verified 2026-07-26

Likely covered — the policy lists Methylmalonic acidemia as a category (Group 2), and this condition is a form of it. Confirm eligibility with a Centre of Excellence.

Group 2 — long-term / lifelong lower-cost interventions

NPRD envisages State Government support for dietary formulae, hormones, and other lower-cost interventions. This is a different route from the central CoE ₹50 lakh pathway; ask your state health department and a CoE which channel applies.

Central CoE funding may also apply depending on current rules — confirm with a notified Centre of Excellence. Do not assume the ₹50 lakh ceiling covers Group 2 by default. Verify

Centres of Excellence (15)
  • All India Institute of Medical Sciences (AIIMS) — New Delhi, Delhi
  • Maulana Azad Medical College — New Delhi, Delhi
  • Sanjay Gandhi Post Graduate Institute of Medical Sciences — Lucknow, Uttar Pradesh
  • Post Graduate Institute of Medical Education and Research (PGIMER) — Chandigarh, Chandigarh
  • Centre for DNA Fingerprinting & Diagnostics with Nizam’s Institute of Medical Sciences — Hyderabad, Telangana
  • King Edward Memorial Hospital — Mumbai, Maharashtra
  • Institute of Post-Graduate Medical Education and Research (IPGMER) — Kolkata, West Bengal
  • Centre for Human Genetics with Indira Gandhi Hospital — Bengaluru, Karnataka
  • Institute of Child Health and Hospital for Children (ICH & HC) — Chennai, Tamil Nadu
  • All India Institute of Medical Sciences (AIIMS) — Jodhpur, Rajasthan
  • Sree Avittam Thirunal Hospital (SAT), Government Medical College — Thiruvananthapuram, Kerala
  • All India Institute of Medical Sciences (AIIMS) — Bhopal, Madhya Pradesh
  • Regional Institute of Medical Sciences (RIMS) — Imphal, Manipur
  • All India Institute of Medical Sciences (AIIMS) — Patna, Bihar
  • Assam Medical College & Hospital — Dibrugarh, Assam

Voluntary contributions / crowdfunding (separate from CoE funding): https://rarediseases.mohfw.gov.in/

Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.

How we counted this

Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.

("Methylmalonic acidemia with homocystinuria type cblF" OR "CblF defect" OR "Cobalamin F defect" OR "Combined defect in adenosylcobalamin and methylcobalamin synthesis, type cblF" OR "Lysosomal membrane cobalamin transporter deficiency" OR "Methylmalonic aciduria with homocystinuria, type cblF" OR "inherited methylmalonic acidemia and homocystinuria" OR "methylmalonic aciduria and homocystinuria type cblF") OR (MESH:"Methylmalonic Aciduria and Homocystinuria, CblF Type") OR ("LMBRD1" OR "LMBRD1 syndrome" OR "LMBRD1-related")

Run this search on Europe PMC

MeSH descriptor terms unioned into the query: Methylmalonic Aciduria and Homocystinuria, CblF Type

ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):

"Methylmalonic acidemia with homocystinuria type cblF" OR "CblF defect" OR "Cobalamin F defect" OR "Combined defect in adenosylcobalamin and methylcobalamin synthesis, type cblF" OR "Lysosomal membrane cobalamin transporter deficiency" OR "Methylmalonic aciduria with homocystinuria, type cblF" OR "inherited methylmalonic acidemia and homocystinuria" OR "methylmalonic aciduria and homocystinuria type cblF" OR "Methylmalonic Aciduria and Homocystinuria, CblF Type"

Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.

Parent-category trials query:

"methylmalonic acidemia"

Query health: suspect — strategies attempted: phrase, mesh; with hits: phrase

Run this search on ClinicalTrials.gov

Confidence reasoning

  • Preferred label is multi-word and distinctive
  • No synonyms dropped by stoplist
  • No label/synonym collisions with other diseases in this corpus
  • Publication count (398) is high for prevalence class "<1 / 1 000 000" — confidence capped at medium

Ingested 2026-07-27T02:13:06.440Z